Published in Front Aging Neurosci on June 12, 2014
Comparison of Metal Levels between Postmortem Brain and Ventricular Fluid in Alzheimer's Disease and Nondemented Elderly Controls. Toxicol Sci (2015) 0.80
Actin dynamics and cofilin-actin rods in alzheimer disease. Cytoskeleton (Hoboken) (2016) 0.80
Editorial: The molecular pathology of cognitive decline: focus on metals. Front Aging Neurosci (2015) 0.78
Cumulative lead exposure is associated with reduced olfactory recognition performance in elderly men: The Normative Aging Study. Neurotoxicology (2015) 0.76
Physiochemical basis of human degenerative disease. Interdiscip Toxicol (2015) 0.75
Some Biochemical Markers in Patients with Alzheimer's Disease. Iran J Public Health (2016) 0.75
Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma. Oxid Med Cell Longev (2015) 0.75
Plasma Cystatin C and High-Density Lipoprotein Are Important Biomarkers of Alzheimer's Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci (2017) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet (1994) 7.07
Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet (2000) 6.61
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
CNS synaptogenesis promoted by glia-derived cholesterol. Science (2001) 6.04
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 4.31
Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci (1998) 4.19
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci (2009) 3.97
Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 3.92
Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A (1999) 3.85
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet (1996) 2.95
The many faces of tau. Neuron (2011) 2.89
Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol (2009) 2.83
Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron (2007) 2.55
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2007) 2.17
Zinc at glutamatergic synapses. Neuroscience (2008) 2.08
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci (2004) 2.07
Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res (2010) 2.07
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) 2.01
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A (2001) 2.00
Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology (2004) 1.96
Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci (2010) 1.93
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci (2008) 1.92
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 1.84
Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J (2000) 1.84
Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem (2004) 1.82
Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci (2010) 1.74
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2002) 1.74
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem (2005) 1.63
Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol (2007) 1.61
In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem (2000) 1.60
Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics (2008) 1.58
Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J Biol Chem (2002) 1.54
Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci (2003) 1.51
Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci U S A (2011) 1.50
Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis (2009) 1.43
Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med (1998) 1.40
Copper in the brain and Alzheimer's disease. J Biol Inorg Chem (2009) 1.40
Metals and Alzheimer's disease. J Alzheimers Dis (2006) 1.39
Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology (1998) 1.38
Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci (2010) 1.38
Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology (2011) 1.37
Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem (2000) 1.36
Classification of mononuclear zinc metal sites in protein structures. Proc Natl Acad Sci U S A (1997) 1.32
Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology (2006) 1.31
Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int (2012) 1.29
Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol (2010) 1.29
Vesicular zinc promotes presynaptic and inhibits postsynaptic long-term potentiation of mossy fiber-CA3 synapse. Neuron (2011) 1.29
Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res (1999) 1.27
Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol (2000) 1.22
Helix orientation of the functional domains in apolipoprotein e in discoidal high density lipoprotein particles. J Biol Chem (2004) 1.22
Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol (2009) 1.21
Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci (2011) 1.17
Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J Biol Chem (2008) 1.16
Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol (2006) 1.13
Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology. Acta Neurol Scand Suppl (2006) 1.13
Metallostasis in Alzheimer's disease. Free Radic Biol Med (2012) 1.13
Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology (2009) 1.08
Evidence that the ZNT3 protein controls the total amount of elemental zinc in synaptic vesicles. J Histochem Cytochem (2007) 1.08
Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J Biol Chem (2004) 1.07
Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain. PLoS One (2011) 1.06
Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.05
The role of apolipoprotein E in the nervous system. Curr Opin Lipidol (1994) 1.04
Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem (2009) 1.03
Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol (2010) 1.02
Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler Thromb Vasc Biol (2003) 1.01
APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals. J Neurochem (2012) 1.01
Alzheimer's disease genetics current status and future perspectives. Int Rev Neurobiol (2009) 1.00
Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol Dis (2004) 0.99
Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. J Neurochem (2009) 0.98
Evidence for impaired amyloid β clearance in Alzheimer's disease. Alzheimers Res Ther (2013) 0.97
GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis (2011) 0.97
Prediction of structures of zinc-binding proteins through explicit modeling of metal coordination geometry. Protein Sci (2010) 0.92
Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging (2013) 0.90
Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol Aging (2012) 0.88
Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry (1999) 0.87
In vitro gamma-secretase cleavage of the Alzheimer's amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc. FEBS J (2005) 0.86
Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int (2012) 0.86
Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. J Alzheimers Dis (2014) 0.85
Zinc depletion reduced Egr-1 and HNF-3beta expression and apolipoprotein A-I promoter activity in Hep G2 cells. Am J Physiol Cell Physiol (2002) 0.85
The role of metals in beta-amyloid peptide aggregation: X-Ray spectroscopy and numerical simulations. Curr Alzheimer Res (2008) 0.82
Clusterin/Apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells. Biogerontology (2006) 0.82
Biophysical studies of the amyloid β-peptide: interactions with metal ions and small molecules. Chembiochem (2013) 0.82
Copper (II) modulates in vitro aggregation of a tau peptide. Peptides (2007) 0.81
Links between copper and cholesterol in Alzheimer's disease. Front Physiol (2013) 0.81
Copper enhances APP dimerization and promotes Aβ production. Neurosci Lett (2013) 0.81
Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. Biometals (2010) 0.81
Alzheimer disease: plasma clusterin predicts degree of pathogenesis in AD. Nat Rev Neurol (2010) 0.80
Probing copper/tau protein interactions electrochemically. Anal Biochem (2013) 0.80
The amyloid precursor protein copper binding domain histidine residues 149 and 151 mediate APP stability and metabolism. J Biol Chem (2012) 0.78
Regulation of intestinal apolipoprotein B mRNA editing levels by a zinc-deficient diet and cDNA cloning of editing protein in hamsters. J Nutr (2000) 0.77
Metallostasis and amyloid β-degrading enzymes. Metallomics (2012) 0.77
Apolipoprotein A-I synthesis and secretion are increased in Hep G2 cells depleted of copper by cupruretic tetramine. J Nutr (1995) 0.76